Fate Therapeutics (FATE) Misses Q1 EPS by 1c

Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.34), $0.01 worse than the analyst estimate of ($0.33).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• DA Davidson flags Duolingo DAU momentum stalling, keeps Neutral at $120
• Bureau Veritas agrees to sell oil and coal testing unit for €470M